.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Dimyristoyl lecithin; perflexane - Generic Drug Details

« Back to Dashboard
Dimyristoyl lecithin; perflexane is the generic ingredient in one branded drug marketed by Imcor Pharms Co and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

This ingredient has thirty-two patent family members in eighteen countries.

There are sixteen drug master file entries for dimyristoyl lecithin; perflexane.

Summary for Generic Name: dimyristoyl lecithin; perflexane

Tradenames:1
Patents:1
Applicants:1
NDAs:1
Drug Master File Entries: see list16
Formulation / Manufacturing:see details

Clinical Trials for: dimyristoyl lecithin; perflexane

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Imcor Pharms Co
IMAGENT
dimyristoyl lecithin; perflexane
INJECTABLE;INTRAVENOUS021191-001May 31, 2002DISCNNo5,798,091<disabled> <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: dimyristoyl lecithin; perflexane

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Imcor Pharms Co
IMAGENT
dimyristoyl lecithin; perflexane
INJECTABLE;INTRAVENOUS021191-001May 31, 20026,280,705<disabled>
Imcor Pharms Co
IMAGENT
dimyristoyl lecithin; perflexane
INJECTABLE;INTRAVENOUS021191-001May 31, 20026,287,539<disabled>
Imcor Pharms Co
IMAGENT
dimyristoyl lecithin; perflexane
INJECTABLE;INTRAVENOUS021191-001May 31, 20025,605,673<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: dimyristoyl lecithin; perflexane

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,720,938 Systems for the formation of microbubbles<disabled in preview>
5,605,673 Stabilized microbubble compositions for ultrasound<disabled in preview>
6,280,705 Kits & systems for ultrasonic imaging<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: dimyristoyl lecithin; perflexane

Country Document Number Estimated Expiration
Australia694135<disabled in preview>
World Intellectual Property Organization (WIPO)9626746<disabled in preview>
Canada2212113<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc